Outcomes and recurrence patterns following curative hepatectomy for hepatocellular carcinoma patients with different China liver cancer staging

被引:9
作者
Li, Changxian [1 ]
Wang, Hongwei [1 ,2 ]
Chen, Ruixiang [1 ]
Zhang, Hui [1 ]
Xu, Yonghua [2 ]
Zhang, Bin [3 ]
Li, Yong [4 ]
Zhang, Changhe [5 ]
Yang, Yue [6 ]
Wang, Xuehao [1 ]
Li, Xiangcheng [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Hepatobiliary Ctr, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China
[2] Yancheng 1 Peoples Hosp, Dept Gen Surg, Yancheng, Jiangsu, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Hepatobiliary Surg, Xuzhou, Jiangsu, Peoples R China
[4] Nanjing Med Univ, Affiliated Suqian Peoples Hosp 1, Dept Gen Surg, Suqian, Jiangsu, Peoples R China
[5] Taizhou Peoples Hosp, Hepatobiliary Surg, Taizhou, Jiangsu, Peoples R China
[6] First Peoples Hosp Changzhou, Hepatobiliary Surg, Changzhou, Jiangsu, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2022年 / 12卷 / 02期
关键词
Hepatocellular carcinoma; recurrence patterns; CNLC staging; risk factors; OS; RISK-FACTORS; RESECTION; SURVIVAL; GUIDELINES; SURGERY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to investigate outcomes and recurrence patterns after hepatectomy for hepatocellular carcinoma (HCC) patients with different China Liver Cancer staging (CNLC), and then analyze the risk factors of different recurrence patterns. A total of 731 HCC patients undergoing curative resection were reviewed from 6 independent institutions. Data on preoperative and clinicopathological parameters, operation and tumor recurrence information, recurrence management and long-term outcomes were analyzed. Our results showed that 1-, 3-, and 5-year OS rate for Ia was 96.6%, 88.5%, and 77.4%, while 1-, 3-, and 5-year of Ib was 84.2%, 65.5%, and 51.3%, respectively. Compared to Ia, the patients in IIa and IIb staging had poorer 1-, 3-, and 5-year OS and DFS. Furthermore, the 1-, 3-, and 5-year OS rate in IIIa was 59.3%, 37.3%, and 27.7%, while the 1-, 3-, and 5-year OS of IIIb was 25.6%, 12.8%, and 0%, respectively. The mostly site of recurrence after liver surgery was intra hepatic recurrence (CNLC Ia: 89.4%; Ib: 65.9%; IIa: 68.9%; IIb: 91.7%; IIIa: 63.8%). However, the CNLC IIIb patients have higher percentage of extrahepatic recurrence (56.5%). The main recurrence pattern of time course was late recurrence in CNLC Ia patients (61.1%). However, the rate of early recurrence in Ib, IIa, IIb, IIIa, IIIb patients was 69.0%, 62.2%, 62.5%, 78.3% and 95.7% respectively. In conclusion, the outcomes and recurrence patterns of HCC patients after resection vary with different CNLC staging, which defined the prognosis of patients with HCC after resection. The HCC patients with CNLC IIIa can also benefit from liver resection. The CNLC staging could be considered in forming management strategies, treatment choice and surveillance for HCC patients.
引用
收藏
页码:907 / 921
页数:15
相关论文
共 33 条
[1]   Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis [J].
Berzigotti, Annalisa ;
Reig, Maria ;
Abraldes, Juan G. ;
Bosch, Jaime ;
Bruix, Jordi .
HEPATOLOGY, 2015, 61 (02) :526-536
[2]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[3]   Hepatocellular carcinoma: clinical frontiers and perspectives [J].
Bruix, Jordi ;
Gores, Gregory J. ;
Mazzaferro, Vincenzo .
GUT, 2014, 63 (05) :844-855
[4]   Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design [J].
Burrel, Marta ;
Reig, Maria ;
Forner, Alejandro ;
Barrufet, Marta ;
Rodriguez de Lope, Carlos ;
Tremosini, Silvia ;
Ayuso, Carmen ;
Llovet, Josep M. ;
Isabel Real, Maria ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1330-1335
[5]  
Byeon Jangmoo, 2012, Korean J Hepatobiliary Pancreat Surg, V16, P93, DOI 10.14701/kjhbps.2012.16.3.93
[6]   Prospective validation of the Barcelona Clinic Liver Cancer staging system [J].
Cillo, U ;
Vitale, A ;
Grigoletto, F ;
Farinati, F ;
Brolese, A ;
Zanus, G ;
Neri, D ;
Boccagni, P ;
Srsen, N ;
D'Amico, F ;
Ciarleglio, FA ;
Bridda, A ;
D'Amico, DF .
JOURNAL OF HEPATOLOGY, 2006, 44 (04) :723-731
[7]  
Department of Medical Administration National Health and Health Commission of the People's Republic of China, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P112, DOI 10.3760/cma.j.issn.1007-3418.2020.02.004
[8]   Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma [J].
Erridge, S. ;
Pucher, P. H. ;
Markar, S. R. ;
Malietzis, G. ;
Athanasiou, T. ;
Darzi, A. ;
Sodergren, M. H. ;
Jiao, L. R. .
BRITISH JOURNAL OF SURGERY, 2017, 104 (11) :1433-1442
[9]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P154, DOI 10.1016/j.jhep.2018.03.018
[10]   Recurrence Patterns After Anatomic or Parenchyma-Sparing Liver Resection for Hepatocarcinoma in a Western Population of Cirrhotic Patients [J].
Famularo, Simone ;
Di Sandro, Stefano ;
Giani, Alessandro ;
Lauterio, Andrea ;
Sandini, Marta ;
De Carlis, Riccardo ;
Buscemi, Vincenzo ;
Uggeri, Fabio ;
Romano, Fabrizio ;
Gianotti, Luca ;
De Carlis, Luciano .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (13) :3974-3981